MedPath

Know Labs Presents Promising Clinical Data on Non-Invasive Glucose Monitoring Technology

• Know Labs presented clinical study results at the AACE Annual Meeting, demonstrating the accuracy of its non-invasive glucose monitoring sensor. • The study involved individuals with diabetes and used venous blood as a reference, employing a machine learning model for data analysis. • Know Labs plans to conduct large-scale clinical trials with its KnowU™ wearable CGM to assess performance in real-world conditions and extreme glycemic ranges. • The company is advancing towards FDA clearance, with the goal of providing accessible and affordable real-time blood glucose information.

Know Labs, Inc. (NYSE American: KNW) presented clinical research at the American Association of Clinical Endocrinology (AACE) Annual Meeting in New Orleans, Louisiana, showcasing the potential of its non-invasive glucose monitoring technology. The oral abstract presentation, delivered on May 9, 2024, highlighted results from a clinical study demonstrating the accuracy and medical application of Know Labs' proprietary sensor.
The presentation, titled "Efficacy of a Non-Invasive Blood Glucose Monitor for Diabetes Management Using a Radiofrequency Sensor and Machine Learning," featured interim results initially announced in March. The study involved individuals with diabetes, utilizing venous blood as a comparative reference. A machine learning model, trained on data collected in a lab setting, was employed to analyze the sensor's performance.

Advancing Towards FDA Clearance

As Know Labs progresses towards FDA clearance in 2024, the company plans to deploy its KnowU™ wearable, a non-invasive continuous glucose monitor (CGM), in extensive, external clinical trials. These trials aim to evaluate the technology's performance during continuous wear, in more realistic environments, and across a broader spectrum of glycemic ranges, specifically below 70 mg/dL and above 350 mg/dL. These studies will help refine the device and improve model techniques.

About Know Labs' Technology

Know Labs' platform technology utilizes spectroscopy to direct electromagnetic energy through a substance, capturing a unique molecular signature. This technology can be integrated into various form factors, including wearable, mobile, and bench-top devices. The patented and patent-pending technology enables the identification and monitoring of analytes that previously required invasive, expensive, and time-consuming lab-based tests. The initial application focuses on a non-invasive glucose monitor, designed to provide users with accessible and affordable real-time blood glucose level information. The product will require U.S. Food and Drug Administration clearance before market introduction.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Reference News

[1]
Know Labs to Present Clinical Research at the 2024 American Association of Clinical Endocrinology Annual Meeting
finance.yahoo.com · May 9, 2024

Know Labs, Inc. announced an oral abstract presentation at the AACE Annual Meeting, showcasing its non-invasive blood gl...

© Copyright 2025. All Rights Reserved by MedPath